08Jul/21
Unprecedented!—FDA accelerates the approval of CD19-ADC
Recently, FDA has accelerated the approval of ADC Therapeutics’ targeted CD19-ADC drug Loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). It is worth mentioning that,Read More…